WO2001081919A2 - Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose - Google Patents
Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose Download PDFInfo
- Publication number
- WO2001081919A2 WO2001081919A2 PCT/US2001/013378 US0113378W WO0181919A2 WO 2001081919 A2 WO2001081919 A2 WO 2001081919A2 US 0113378 W US0113378 W US 0113378W WO 0181919 A2 WO0181919 A2 WO 0181919A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gip
- individual
- diabetes
- type
- glucose
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Definitions
- the present invention is directed to, for example, methods and kits for determining whether an individual is susceptible to developing impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or Type-2 diabetes.
- the methods include administering a GIP or GIP variant to an individual, measuring the response of the individual and determining whether the individual is susceptible to developing IGT, Type-2 diabetes, or IFG.
- IGT, IFG, and Type-2 diabetes are those proposed in 1997 by the "Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.” See Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20: 1183 (1997). It is understood, however, that the criteria for diagnosing IGT, IFG, and Type-2 diabetes are set by institutional bodies and may be changed from time to time and may vary from organisation to organisation. Notwithstanding these variations, the terms IGT, IFG, and Type-2 diabetes, as used herein, are intended to be interpreted broadly and to be inclusive of the varying classification criteria used in the art. "Susceptible to developing IGT, IFG, or Type-2 diabetes" means at risk for developing one or more of these conditions.
- GIP variant is a polypeptide comprising amino acids 19-30 of SEQ ID NO: 1 (see Morrow et al., Canada J. Physiol Pharmacol. 74:65 (1996)), where 1-5 or more amino acid substitutions, deletions, or additions can be made within this 19-30 amino acid sequence.
- the present invention is directed to methods and kits using GIP or GIP variant to determine whether an individual is susceptible to developing Type-2 diabetes, IGT, or IFG.
- the above method can be applied to test any individual, even if the individual is not considered to fall within a risk category for developing Type-2 diabetes, IGT, or IFG.
- the above method can also be applied more selectively to those who are at risk for developing these diseases, namely individuals exhibiting at least one indicia of susceptibility for developing Type-2 diabetes, IGT, or IFG.
- the present invention includes applying the above method to, for example, a blood relative of at least one individual who has Type-2 diabetes, IGT, or IFG; an individual who is 45 years of age or older; an individual who is obese; or an individual who already has IGT or IFG (in the context of diagnosing risk for developing Type-2 diabetes).
- the preferred method of assessing the response of an individual to GIP or GIP variant alone or with nutrient is to assess plasma levels of insulin, C-peptide, glucose, or levels of insulin secretion, insulin secretion rate, or any combination thereof.
- insulin response denotes the insulin level in an individual to whom a GIP or GIP variant has been administered.
- C- peptide response denotes the C-peptide level in an individual to whom a GIP or GIP variant has been administered.
- glucose response denotes the glucose level in an individual to whom a GIP or GIP variant has been administered. This assessment is made optionally, before, after, or during the administration step.
- one or more of these levels are assessed before administration and then after administration in order to assess the difference in the levels, which indicates the response to the adn inistration.
- Methods of assessing these levels, either in the plasma or elsewhere, are known to the skilled artisan. See, for example, Insulin: Andersen, et al., "Enzyme immunoassay of intact insulin in serum and plasma," Clinical Chemistry 39: 578-582 (1993) (insulin levels); Heding, L. G., "Specific and direct radioimmunoassay for human C-peptide in serum,” Diabetologia 11: .
- the constant can also be more complex in the sense that it can based on data from particular sub-populations of individuals, where the sub- populations are selected to provide a more accurate control for the test individual or individuals.
- the constant is predetermined, meaning that the constant has been calculated prior to the administration of the above described method.
- the "determining step" involves a comparison of the response of the tested individual or individuals to the constant and a determination, based on the comparison, of whether the tested individual or individuals is susceptible to developing IGT, IFG, or Type-2 diabetes.
- the mathematical difference between the response of the tested individual or individuals and the constant is calculated and this amount is compared to a second constant.
- the kit includes at least one syringe with GIP or GIP variant, or a combination thereof: (1) in powder form, for example lyophilized, to be reconstituted with, for example, saline, or (2) in a liquid form.
- the kit can either include or not include a nutrient.
- the kit includes at least one syringe containing one or more nutrients, preferably glucose, (1) in powder form, for example lyophilized, to be reconstituted with, for example, saline, or (2) in a suitable stable liquid form.
- the kit further includes at least one means for determining whether the individual is susceptible to developing IGT, IFG, or Type-2 diabetes.
- the means as described above can include a chart or table, or other similar device which can be used to quickly select the appropriate above-described first and second constants or make the above described calculations.
- the means can also include software or a database for making the calculation or other similar electronic means.
- the kit can also include a password or other similar code which enables a user to log on to an internet site or other suitable venue as described above to make the calculations described above.
- Subjects Ten healthy control subjects, ten Type-2 diabetic patients, and 21 first- degree relatives of Type-2 diabetic patients were studied. Subject/patient characteristics are presented in Table 1. The groups were matched for sex, obesity, and age. Non-diabetic participants were subjected to an oral glucose tolerance test (75 g; Boebringer O.G.T., Roche Diagnostics, Mannheim, Germany) with the determination of capillary glucose in the fasting state and 120 min after the ingestion of glucose. 1 subject with diabetes was excluded from the group of relatives. In healthy control subjects, any first- or second-degree relatives with Type-2 diabetes were excluded by history taking.
- Blood pressure was determined according to the Riva-Rocci method.
- Five Type-2-diabetic patients had been treated with diet alone, and 5 patients received oral antidiabetic treatment (glibenclamide, 3,5 mg/d, in 1 case, acarbose 150 mg/d in 3 cases, metformin, 1700 mg/d in 1 case). None of the patients had been treated with insulin. In these patients, the usual antidiabetic medication was withdrawn the day before the study.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020027014447A KR20020097236A (en) | 2000-04-27 | 2001-04-26 | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
AU2001257278A AU2001257278A1 (en) | 2000-04-27 | 2001-04-26 | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
CA002405900A CA2405900A1 (en) | 2000-04-27 | 2001-04-26 | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
EP01930773A EP1356295A2 (en) | 2000-04-27 | 2001-04-26 | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55977900A | 2000-04-27 | 2000-04-27 | |
US09/559,779 | 2000-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001081919A2 true WO2001081919A2 (en) | 2001-11-01 |
WO2001081919A3 WO2001081919A3 (en) | 2003-04-24 |
Family
ID=24234987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/013378 WO2001081919A2 (en) | 2000-04-27 | 2001-04-26 | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1356295A2 (en) |
KR (1) | KR20020097236A (en) |
AU (1) | AU2001257278A1 (en) |
CA (1) | CA2405900A1 (en) |
WO (1) | WO2001081919A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
EP1857818A1 (en) * | 2006-05-15 | 2007-11-21 | DIGILAB BioVisioN GmbH | Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith |
WO2007132291A2 (en) * | 2006-05-15 | 2007-11-22 | Digilab, Inc. | Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes |
US7875587B2 (en) | 1999-03-29 | 2011-01-25 | Uutech Limited | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US10317359B2 (en) | 2016-01-05 | 2019-06-11 | Ravi Kumar Meruva | Differential carbon dioxide sensor |
US20200400686A1 (en) * | 2013-09-20 | 2020-12-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0479210A2 (en) * | 1990-10-05 | 1992-04-08 | Sanwa Kagaku Kenkyusho Co., Ltd. | GIP analogues and use thereof |
-
2001
- 2001-04-26 CA CA002405900A patent/CA2405900A1/en not_active Abandoned
- 2001-04-26 AU AU2001257278A patent/AU2001257278A1/en not_active Abandoned
- 2001-04-26 KR KR1020027014447A patent/KR20020097236A/en not_active Application Discontinuation
- 2001-04-26 WO PCT/US2001/013378 patent/WO2001081919A2/en not_active Application Discontinuation
- 2001-04-26 EP EP01930773A patent/EP1356295A2/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0479210A2 (en) * | 1990-10-05 | 1992-04-08 | Sanwa Kagaku Kenkyusho Co., Ltd. | GIP analogues and use thereof |
Non-Patent Citations (4)
Title |
---|
B. NYHOLM, M. WALKER, C.H. GRAVHLOT, P.A. SHEARING, J. STURIS, K.G.M.M. ALBERTI, J.J. HOLST, O. SCHMITZ: "Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrate and gut incretin hormones in healthy offsspring of type II(non-insulin-dependent) dibetic parents: evidence of several aberrations" DIABETOLOGIA, vol. 42, 1999, pages 1314-1323, XP002208949 * |
J.J. HOLST, J. GROMADA, M.A. NAUCK: "The pathogenesis of NIDDM involves a defective expression of the GIP receptor" DIABETOLOGIA, vol. 40, 1997, pages 984-986, XP002208950 * |
M.A. NAUCK, M.M. HEIMESAAT, C. ORSKOV, J.J. HOLST, R. EBERT, W. CREUTZFELDT: "Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus" J. CLIN.INVEST., vol. 91, no. 1, 1993, pages 301-307, XP001095159 * |
N.N. RUDOWITSCH, D.DICK, M.A. NAUCK, H. SCHATZ, A.F.H. PFEIFFER: "Modified hyperglycemic clamp to detect phenotypic marker of genetic defects leading to type 2 dibetes" DIABETOLOGIA, vol. 43, no. sup.1, August 2000 (2000-08), page A142 XP001095169 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875587B2 (en) | 1999-03-29 | 2011-01-25 | Uutech Limited | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US8895498B2 (en) | 2005-02-11 | 2014-11-25 | Astrazeneca Pharmaceuticals, Lp | GIP and exendin hybrid polypeptides |
WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
US9133260B2 (en) | 2005-02-11 | 2015-09-15 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
EA011653B1 (en) * | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Gip analog and hybrid polypeptides with selectable properties |
WO2006086769A3 (en) * | 2005-02-11 | 2006-11-02 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
EP2392595A1 (en) * | 2005-02-11 | 2011-12-07 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
WO2007132291A3 (en) * | 2006-05-15 | 2008-12-18 | Digilab Inc | Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes |
WO2007131778A3 (en) * | 2006-05-15 | 2008-03-06 | Digilab Biovision Gmbh | Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith |
EP1857818A1 (en) * | 2006-05-15 | 2007-11-21 | DIGILAB BioVisioN GmbH | Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith |
WO2007131778A2 (en) * | 2006-05-15 | 2007-11-22 | Digilab Biovision Gmbh | Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith |
WO2007132291A2 (en) * | 2006-05-15 | 2007-11-22 | Digilab, Inc. | Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
US9447162B2 (en) | 2007-02-15 | 2016-09-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8981047B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8546327B2 (en) | 2008-06-17 | 2013-10-01 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US9790263B2 (en) | 2009-06-16 | 2017-10-17 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US9783592B2 (en) | 2010-05-13 | 2017-10-10 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US10730923B2 (en) | 2011-06-22 | 2020-08-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9758562B2 (en) | 2011-06-22 | 2017-09-12 | Indiana University and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US10174093B2 (en) | 2011-06-22 | 2019-01-08 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US20200400686A1 (en) * | 2013-09-20 | 2020-12-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain |
US10317359B2 (en) | 2016-01-05 | 2019-06-11 | Ravi Kumar Meruva | Differential carbon dioxide sensor |
Also Published As
Publication number | Publication date |
---|---|
KR20020097236A (en) | 2002-12-31 |
CA2405900A1 (en) | 2001-11-01 |
EP1356295A2 (en) | 2003-10-29 |
WO2001081919A3 (en) | 2003-04-24 |
AU2001257278A1 (en) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001081919A2 (en) | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose | |
CN1942767A (en) | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose | |
Meier et al. | Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes | |
Rickels et al. | High residual C-peptide likely contributes to glycemic control in type 1 diabetes | |
Knop et al. | Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? | |
Vilsbøll et al. | The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of etiology and phenotype | |
Vilsbøll et al. | Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | |
Gavin III et al. | Report of the expert committee on the diagnosis and classification of diabetes mellitus | |
DeFronzo et al. | Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake | |
DeFronzo et al. | Preservation of β-cell function: the key to diabetes prevention | |
Yabe et al. | Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients | |
Knop et al. | The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance | |
US8367418B2 (en) | Method and system to provide personalized pharmaceutical compositions and dosages | |
Calanna et al. | Alpha-and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes | |
Kettunen et al. | Human physiology of genetic defects causing beta-cell dysfunction | |
Rachman et al. | Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy | |
Svensson et al. | A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephrophathy | |
Meier et al. | Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects | |
Ito et al. | Impact of glucagon response on early postprandial glucose excursions irrespective of residual β‐cell function in type 1 diabetes: a cross‐sectional study using a mixed meal tolerance test | |
Han et al. | Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-β-d-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria | |
Schou et al. | Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight | |
Schrader et al. | Impaired glucose-induced glucagon suppression after partial pancreatectomy | |
Safarzad et al. | Lower serum zinc level is associated with higher fasting insulin in type 2 diabetes mellitus (T2DM) and relates with disturbed glucagon suppression response in male patients | |
Nandhini et al. | Definition, diagnostic criteria, screening, diagnosis, and classification of diabetes and categories of glucose intolerance | |
Ilag et al. | Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578954 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001257278 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405900 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027014447 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001930773 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018117716 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014447 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001930773 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001930773 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027014447 Country of ref document: KR |